InSilicoTrials

InSilicoTrials is a leading technology company specializing in drug development through AI-powered simulation. The platform offers pharmaceutical and biotech companies access to a vast library of computational models for simulating drug interactions and predicting outcomes. Founded in 2016 and headquartered in the United States, the company received a recent €2.00M grant investment at 30 September 2020. By leveraging digital patient twins and advanced AI algorithms, InSilicoTrials provides a more cost-effective approach to drug development, reducing the need for early-stage human trials and improving decision-making throughout the process. With a focus on biotechnology and healthcare industries, InSilicoTrials is innovating life sciences, making strides in facilitating the discovery of new treatments.